How to Prescribe Compounded Semaglutide in 2026: A Provider's Compliance & Sourcing Guide

If you run a GLP-1 weight-management line, or are weighing one, the question isn't whether patients want compounded semaglutide. It's whether you can keep prescribing it without stepping on a compliance landmine or personally vetting a pharmacy's paperwork. Knowing how to prescribe compounded semaglutide in 2026 now means understanding a materially different regulatory picture than a year ago. The rules moved fast, and a lot of the guidance still circulating online is out of date. This guide walks a licensed prescriber through where compounded semaglutide actually stands now, when you may prescribe it, what you have to document, and how to source it so the provenance holds up under scrutiny.

This article is written for licensed healthcare providers. It is educational, is not legal or medical advice, and does not describe patient-directed dosing. Regulatory statements are date-stamped; because this area is unsettled, re-verify against the primary FDA sources linked below before you rely on any point.

Where compounded GLP-1s stand in 2026

The short version: the shortage-era free-for-all is over, and compounded semaglutide is now generally a 503A patient-specific product, not a batch commodity.

The timeline that matters:

• February 2025: semaglutide removed from the FDA drug shortage list. The shortage designation was the legal basis under which many pharmacies and outsourcing facilities produced compounded copies of the branded drug. Once the shortage resolved, that basis narrowed sharply. The FDA's FD&C Act provisions that apply to human drug compounding and its compounding inspections and oversight FAQ explain how the agency frames compounding of a drug that is commercially available and no longer in shortage.
• April 2026: FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulk-drug substances list, with a public comment period that ran into mid-2026. In plain terms, this targets the office-stock and outsourcing-facility route for these molecules. Because it is a proposal under comment, the details can still shift, so check the current FD&C Act compounding provisions before acting on it.
• As of mid-2026, the practical, defensible path for a provider is 503A patient-specific compounding: a compound made for an individual patient against a valid prescription, with a documented clinical rationale, typically dispensed in limited per-patient quantities rather than produced in anticipation of orders.

So can doctors prescribe compounded semaglutide in 2026? In many cases, yes, but the "why" has changed. It is no longer "the branded drug is unavailable." It has to be a patient-specific clinical reason that a compounded formulation is needed for this patient. If you want the deeper regulatory map of who compounds what, our guide to the difference between 503A and 503B compounding pharmacies lays out both designations and where GLP-1s land across them.

When a provider may prescribe compounded semaglutide

A valid prescription for a compounded drug rests on a clinical determination that the compounded product is necessary for the particular patient, not on cost, convenience, or patient preference alone. Reasonable, documentable rationales a compounded formulation can address include:

• A documented need for a formulation, strength, or excipient profile the approved product does not offer (for example, an allergy or intolerance to an inactive ingredient in the commercial product).
• A clinically justified dose or titration step that the manufactured dosing options do not accommodate.
• A route or delivery consideration that is medically indicated and specific to the patient.

"The brand is expensive" or "the patient would rather have the compounded version" is not, on its own, a sufficient basis now that the shortage has resolved. That distinction is the difference between a defensible chart and an indefensible one.

Document the clinical reason a compounded formulation is needed for this specific patient, contemporaneously, in the record, before the script goes out and not after a question is raised.

For a broader look at building a compliant service line around this and other therapies (intake, eligibility discipline, and workflow), see how to add peptide therapy to your practice.

The 503A patient-specific model, in plain terms

503A compounding is regulated primarily by state boards of pharmacy under United States Pharmacopeia (USP) standards, and it is built around the patient-specific prescription, the statutory framework the FDA describes in the FD&C Act's Section 503A provisions. A few practical implications for prescribers:

• It's made for a named patient. There is no legitimate "order 50 vials of compounded semaglutide for the clinic fridge" under 503A. That is office stock, which is the 503B and outsourcing-facility lane the April 2026 proposal is tightening for these molecules.
• Quantities are patient-scaled. Compounding is tied to the individual prescription and reasonable anticipated need, not to speculative volume.
• Beyond-use dating is shorter and formulation-dependent than a manufactured product's shelf life, which affects how much you prescribe at once and how you counsel on storage.

Understanding the 503A semaglutide requirements up front keeps you from writing something a compliant pharmacy will (rightly) refuse to fill.

What to verify before you prescribe

Sourcing is where most of the risk now lives. Before a compounded semaglutide script leaves your desk, three things should be true, and provable:

1. The pharmacy is licensed in your patient's state

A compounding pharmacy must hold the appropriate license to ship into the state where your patient receives the medication. A pharmacy that is perfectly legitimate in one state may not be authorized to dispense into another. This is easy to get wrong when you're telehealth-first and your patients span state lines.

2. There is a current, matching Certificate of Analysis (COA)

The COA is the batch-level record of identity, strength/potency, and purity for what was actually made. It is the single best objective signal that you're prescribing verified material rather than gray-market product. Compounding quality and testing expectations, along with the FDA's oversight of them, are laid out in the agency's compounding inspections and oversight FAQ. If you can't see a COA tied to the batch your patient will receive, treat that as a red flag.

3. The provenance is traceable

Which lab, which batch, which API source. If a question ever arises about a patient's product, "I can identify exactly what they received and from where" is a fundamentally stronger position than "the platform shipped something."

How to prescribe compounded semaglutide: the workflow, step by step

1. Intake & evaluation. Establish a bona fide provider-patient relationship, take the history, and confirm the clinical picture supports a GLP-1.
2. Document the medical rationale. Documenting the medical rationale for compounded semaglutide, specifically why a compounded formulation is indicated for this patient rather than the approved product, is the step that carries the compliance weight.
3. Confirm eligibility & sourcing. Verify the compound is legally prescribable, and that the fulfilling pharmacy is licensed in the patient's state with a current COA.
4. Write and sign the patient-specific prescription. Appropriate quantity and beyond-use considerations, for the named patient.
5. Verified fulfillment. The script routes to a qualified pharmacy and ships to the patient, with the batch and COA captured against the record.
6. Follow-up & outcome tracking. Response, tolerability, and titration, which is both good care and good documentation.

None of this is exotic. The failure mode is when steps 2 through 5 live in different systems (or nobody's system), and you can't reconstruct the chain later.

Why sourcing is now a liability question, not just a quality one

When the shortage allowance covered you, sourcing felt like a quality preference. In 2026 it is closer to a liability control. If a compounded semaglutide product is ever implicated in an adverse event or a regulatory inquiry, the questions are predictable: Was there a valid patient-specific rationale? Was the pharmacy licensed to ship to that patient's state? Can you produce the COA for that batch? A "yes, here it is" to all three is the position you want to be able to take by default, not something you have to go excavate from emails and fax confirmations.

How a verified marketplace removes the guesswork

This is the problem PEPTPlus is built to take off your plate. Rather than personally vetting each pharmacy's licensure and paperwork, you prescribe from a catalog where:

• Eligibility is enforced by data, not judgment. You only ever see compounds that are legally prescribable, so you can't accidentally order something ineligible.
• Scripts route only to pharmacies licensed in your patient's state, matched by purity, price, and delivery time, automatically and auditably.
• Every batch carries a COA and traceable provenance, captured against the patient's record, so you can always say exactly what your patient received and from which verified source.
• Outcomes track back into your portal, closing the loop from prescription to result.

It's a flat monthly subscription with no per-prescription fee, giving you the compliance and sourcing infrastructure of a much larger operation without building supply-chain relationships yourself. If you're evaluating whether to keep a GLP-1 line at all, being able to prescribe verified compounds in a few clicks, with the licensure, COA, and provenance already handled, is what turns "compliance landmine" back into "manageable service line." You can see how the full prescribe-to-fulfillment flow works on the PEPTPlus provider platform overview.

Staying current as the rules keep moving

The compounded GLP-1 legal status changed multiple times through 2026 and is not finished. Two habits keep you safe: date-stamp your own understanding (know when a rule you're relying on was true), and anchor to primary sources, namely the FD&C Act compounding provisions and the FDA's compounding oversight FAQ, rather than secondhand summaries. The same discipline applies to peptides, where "reclassified" is often misread as "approved"; our breakdown of the 2026 BPC-157 peptide reclassification for prescribers untangles that. And if you want the underlying map of which pharmacy type can do what, keep the 503A vs 503B compounding pharmacy guide bookmarked.

Prescribe compounded GLP-1s with the compliance built in

You don't have to choose between offering compounded semaglutide and sleeping at night. PEPTPlus enforces FDA-eligibility by data, routes only to verified pharmacies licensed in your patient's state, and shows you the COA for every batch, so the sourcing and state-license guesswork simply isn't yours to carry.

Start prescribing verified compounds in a few clicks →